The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Open accessAbstract
Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to their highly invasive nature and relatively low response to therapeutics. There is an absence of specific treatment strategies for this tumor subgroup, and hence TNBC is managed with conventional therapeutics, often leading to systemic relapse. In terms of histology and transcription profile these cancers have similarities to BRCA-1-linked breast cancers, and it is hypothesized that BRCA1 pathway is non-functional in this type of breast cancer. In this review article, we discuss the different receptors expressed by TNBC as well as the diversity of different signaling pathways targeted by TNBC therapeutics, for example, Notch, Hedgehog, Wnt/b-Catenin as well as TGF-beta signaling pathways. Additionally, many epidermal growth factor receptor (EGFR), poly (ADP-ribose) polymerase (PARP) and mammalian target of rapamycin (mTOR) inhibitors effectively inhibit the TNBCs, but they face challenges of either resistance to drugs or relapse. The resistance of TNBC to conventional therapeutic agents has helped in the advancement of advanced TNBC therapeutic approaches including hyperthermia, photodynamic therapy, as well as nanomedicine-based targeted therapeutics of drugs, miRNA, siRNA, and aptamers, which will also be discussed. Artificial intelligence is another tool that is presented to enhance the diagnosis of TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Carbon Nanotubes--the Route Toward Applications
Baughman, R. H., Zakhidov, A. A., & de Heer, W. A. (2002) · Science · doi:10.1126/science.1060928 · Cited by 10,267
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics
Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., & Weiss, S. (2005) · Science · doi:10.1126/science.1104274 · Cited by 7,790
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145 · cited 1×
“PDT based on nanoparticles exploits a photosensitizing agent creating ROS and apoptosis avoiding healthy tissue damage [175].”
BackgroundTriple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Adjuvant therapy is also a critical strategy to avoid the risk of metastases with concomitant rapid progression and tumor recurrence activity [116].”
BackgroundLuminescent Carbon Nanodots: Emergent Nanolights
Baker, S. N., & Baker, G. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200906623 · Cited by 4,921
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 3×
“These materials are used due to their low cytotoxicity, for example, gold nanoparticles are not cytotoxic making them suitable candidates for nanomedicine [172].”
BackgroundInfluentialArtificial intelligence in healthcare: past, present and future
Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., Wang, Y., Dong, Q., Shen, H., & Wang, Y. (2017) · Stroke and Vascular Neurology · doi:10.1136/svn-2017-000101 · Cited by 4,837
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“, liposomal doxorubicin (DoxilTM) [150], albumin-bound paclitaxel or Nab-Paclitaxel (AbraxaneTM) [151] and polyethylene glycol (PEG-1) Asparaginase (OncasparTM) [152].”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47136 · Cited by 3,492
Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations
Jeevanandam, J., Barhoum, A., Chan, Y. S., Dufresne, A., & Danquah, M. K. (2018) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.9.98 · Cited by 3,297
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910 · cited 1×
“Some examples of these delivery vehicles include micelles [154], luminescent carbon nanodots [155], nanodiamonds (NDs) [156], carbon nanotubes (CNTs) [157,158], Au-nano matryoshkas [159] as well as SPIONs (superparamagnetic iron oxide nanoparticles (NPs)) [160,161] etc.”
BackgroundBreast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789 · cited 2×
“The importance of microRNA (miRNA/miR) related with cancer treatment has recently increased due to their potential as diagnostic biomarkers [108].”
BackgroundSt-Jacques, B., Hammerschmidt, M., & McMahon, A. P. (1999) · Genes & Development · doi:10.1101/gad.13.16.2072 · Cited by 1,735
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Shukla, R., Bansal, V., Chaudhary, M., Basu, A., Bhonde, R. R., & Sastry, M. (2005) · Langmuir · doi:10.1021/la0513712 · Cited by 1,687
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M., & Sporn, M. B. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32345-7 · Cited by 1,598
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Self-citationBiological applications of magnetic nanoparticles
Colombo, M., Carregal-Romero, S., Casula, M. F., Gutiérrez, L., Morales, M. P., Böhm, I. B., Heverhagen, J. T., Prosperi, D., & Parak, W. J. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15337h · Cited by 1,315
Near-Infrared Resonant Nanoshells for Combined Optical Imaging and Photothermal Cancer Therapy
Gobin, A. M., Lee, M. H., Halas, N. J., James, W. D., Drezek, R. A., & West, J. L. (2007) · Nano Letters · doi:10.1021/nl070610y · Cited by 1,314
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Incidence and Mortality and Epidemiology of Breast Cancer in the World
Ghoncheh, M., Pournamdar, Z., & Salehiniya, H. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.s3.43 · Cited by 1,115
The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis
Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M., & Adams, R. H. (2009) · Cell · doi:10.1016/j.cell.2009.03.025 · Cited by 1,107
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Krishnamurthy, N., & Kurzrock, R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.002 · Cited by 1,026
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
Breast cancer intrinsic subtype classification, clinical use and future trends.
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015) · Europe PMC (PubMed Central) · Cited by 921
A New Era for Cancer Treatment: Gold‐Nanoparticle‐Mediated Thermal Therapies
Kennedy, L. C., Bickford, L. R., Lewinski, N. A., Coughlin, A. J., Hu, Y., Day, E. S., West, J. L., & Drezek, R. A. (2011) · Small · doi:10.1002/smll.201000134 · Cited by 885
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 856
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 835
Nanotechnology: convergence with modern biology and medicine
Roco, M. C. (2003) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(03)00068-5 · Cited by 763
Cheng, J.-Z., Ni, D., Chou, Y.-H., Qin, J., Tiu, C.-M., Chang, Y.-C., Huang, C.-S., Shen, D., & Chen, C.-M. (2016) · Scientific Reports · doi:10.1038/srep24454 · Cited by 755 · cited 1×
“Some examples of these techniques are computer-aided detection (CADe), case-based reasoning (CBR), osteodetect machine learning, computer-aided diagnosis (CADx), explainable artificial inteligence (XAI) and rainbow boxes [230,231].”
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Review: Nanocomposites in Food Packaging
Arora, A., & Padua, G. W. (2010) · Journal of Food Science · doi:10.1111/j.1750-3841.2009.01456.x · Cited by 735
Mechanisms of chemoresistance in cancer stem cells
Abdullah, L. N., & Chow, E. K. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-3 · Cited by 721
Arias, L. S., Pessan, J. P., Vieira, A. P. M., Lima, T. M. T. D., Delbem, A. C. B., & Monteiro, D. R. (2018) · Antibiotics · doi:10.3390/antibiotics7020046 · Cited by 714
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Toxicity of Nanoparticles and an Overview of Current Experimental Models.
Bahadar, H., Maqbool, F., Niaz, K., & Abdollahi, M. R. (2016) · PubMed · doi:10.7508/ibj.2016.01.001 · Cited by 643
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 2×
“Some novel drugs target Frizzled receptors, for example, OMP-18R5 an antibody targeting Frizzled receptors diminishes proliferation of tumor cells in the lung, breast, colon, and pancreatic tumors [48].”
BackgroundNanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
Aptamers: Problems, Solutions and Prospects
Lakhin, A. V., Tarantul, V. Z., & Gening, L. V. (2013) · Acta Naturae · doi:10.32607/20758251-2013-5-4-34-43 · Cited by 577
Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment
Chow, E. K., Zhang, X.-Q., Chen, M., Lam, R., Robinson, E., Huang, H., Schaffer, D., Osawa, E., Goga, A., & Ho, D. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001713 · Cited by 556
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
Weijzen, S., Rizzo, P., Braid, M., Vaishnav, R., Jonkheer, S. M., Zlobin, A., Osborne, B. A., Gottipati, S., Aster, J. C., Hahn, W. C., et al. (2002) · Nature Medicine · doi:10.1038/nm754 · Cited by 550
Poly(ADP-ribose) Binds to Specific Domains in DNA Damage Checkpoint Proteins
Pleschke, J. M., Kleczkowska, H. E., Strohm, M., & Althaus, F. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006520200 · Cited by 541
Current approaches in treatment of triple-negative breast cancer.
Wahba, H. A., & El-Hadaad, H. A. (2015) · PubMed · doi:10.7497/j.issn.2095-3941.2015.0030 · Cited by 538
Molecular Mechanisms and Biological Functions of siRNA
Department of Biology, D. B., Dana, H., Chalbatani, G. M., Mahmoodzadeh, H., Gharagouzlo, E., Cancer Research Center, C. I. O. I., Karimloo, R., Department of Medicine, Z. M. S., Rezaiean, O., Moradzadeh, A., et al. (2017) · International Journal of Biomedical Science · doi:10.59566/ijbs.2017.13048 · Cited by 505
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
De Vos, M., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 492
Leukocyte composition of human breast cancer
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 479
Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., & Clemons, M. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474
Magnetic Nanoparticles in Cancer Theranostics
Gobbo, O. L., Sjaastad, K., Radomski, M. W., Volkov, Y., & Prina-Mello, A. (2015) · Theranostics · doi:10.7150/thno.11544 · Cited by 462
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis
Zhao, L., Gu, C., Gan, Y., Shao, L., Chen, H., & Zhu, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.005 · Cited by 438
Ferreira, C. S. M., Matthews, C. S., & Missailidis, S. (2006) · Tumor Biology · doi:10.1159/000096085 · Cited by 407
Multi-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
Notch signaling: An emerging therapeutic target for cancer treatment
Yuan, X., Wu, H., Xu, H., Xiong, H., Chu, Q., Yu, S., Wu, G. S., & Wu, K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.048 · Cited by 402
Hedgehog Signaling Pathway is a New Therapeutic Target for Patients with Breast Cancer
Kubo, M., Nakamura, M., Tasaki, A., Yamanaka, N., Nakashima, H., Nomura, M., Kuroki, S., & Katano, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0416 · Cited by 399
Wimberly, H., Brown, J. R., Schalper, K., Haack, H., Silver, M. R., Nixon, C., Bossuyt, V., Pusztai, L., Lannin, D. R., & Rimm, D. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0133 · Cited by 397
Triple-negative breast cancer: is there a treatment on the horizon?
Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X. (2017) · Oncotarget · doi:10.18632/oncotarget.12284 · Cited by 394
Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., & Sotiriou, C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy024 · Cited by 382
Ayala-Orozco, C., Urban, C., Knight, M. W., Urban, A. S., Neumann, O., Bishnoi, S. W., Mukherjee, S., Goodman, A. M., Charron, H., Mitchell, T., et al. (2014) · ACS Nano · doi:10.1021/nn501871d · Cited by 381
Geyer, F. C., Lacroix-Triki, M., Savage, K., Arnedos, M., Lambros, M. B., MacKay, A., Natrajan, R., & Reis-Filho, J. S. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.205 · Cited by 373
Gennari, A., Sormani, M. P., Pronzato, P., Puntoni, M., Colozza, M., Pfeffer, U., & Bruzzi, P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm252 · Cited by 371
Inorganic Nanoparticles as Protein Mimics
Kotov, N. A. (2010) · Science · doi:10.1126/science.1190094 · Cited by 370
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents
Isakoff, S. J. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24ff7 · Cited by 348
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Abdulkarim, B. S., Cuartero, J., Hanson, J., Deschênes, J., Lesniak, D., & Sabri, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4714 · Cited by 345
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 343
Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer
久保, 真. (2005) · Medical Entomology and Zoology · Cited by 342
Hayashi, K., Nakamura, M., Sakamoto, W., Yogo, T., Miki, H., Ozaki, S., Abe, M., Matsumoto, T., & Ishimura, K. (2013) · Theranostics · doi:10.7150/thno.5860 · Cited by 329
Geisler, S. B., Lønning, P. E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., & Børresen‐Dale, A. (2001) · PubMed · Cited by 326
Jézéquel, P., Loussouarn, D., Guérin-Charbonnel, C., Campion, L., Vanier, A., Gouraud, W., Lasla, H., Guette, C., Valo, I., Verrièle, V., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0550-y · Cited by 321
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304
Liang, R., Liu, L., He, H., Chen, Z., Han, Z., Luo, Z., Wu, Z., Zheng, M., Ma, Y., & Cai, L. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.051 · Cited by 300
Strom, C. E., Johansson, F., Uhlen, M., Szigyarto, C. A.-K., Erixon, K., & Helleday, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1241 · Cited by 296
Wnt signaling in triple-negative breast cancer
Pohl, S.-G., Brook, N., Agostino, M., Arfuso, F., Kumar, A. P., & Dharmarajan, A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.14 · Cited by 296
mTOR inhibitors in cancer therapy
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Mark Evers, B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.005 · Cited by 291
Chan, S. M., Weng, A. P., Tibshirani, R., Aster, J. C., & Utz, P. J. (2007) · Blood · doi:10.1182/blood-2006-08-039883 · Cited by 281
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.011 · Cited by 275
Notch inhibitors for cancer treatment
Espinoza, I., & Miele, L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.02.003 · Cited by 273
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., Jakubowicz, J., Cybulski, C., Wisniowski, R., Godlewski, D., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3100-x · Cited by 269
Anticancer Mechanisms of Cannabinoids
Velasco, G., Sánchez, C., & Guzmán, M. (2016) · Current Oncology · doi:10.3747/co.23.3080 · Cited by 265
Targeting cancer stem cells: a new therapy to cure cancer patients.
Hu, Y., & Fu, L. (2012) · Europe PMC (PubMed Central) · Cited by 264
The new TNM-based staging of breast cancer
Cserni, G., Chmielik, E., Cserni, B., & Tot, T. (2018) · Virchows Archiv · doi:10.1007/s00428-018-2301-9 · Cited by 259
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr371 · Cited by 256
Wnt signaling in triple negative breast cancer is associated with metastasis
Dey, N., Barwick, B. G., Moreno, C. S., Ordanic-Kodani, M., Chen, Z., Oprea-Ilies, G., Tang, W., Catzavelos, C., Kerstann, K. F., Sledge, G. W., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-537 · Cited by 255
Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?
Speirs, V., Parkes, A., Kerin, M. J., Walton, D. S., Carleton, P. J., Fox, J. N., & Atkin, S. L. (1999) · PubMed · Cited by 255
Triple-Negative Breast Cancer: Epidemiology and Management Options
Dawood, S. (2010) · Drugs · doi:10.2165/11538150-000000000-00000 · Cited by 253
Intravenous magnetic nanoparticle cancer hyperthermia
Hainfeld, J., & Huang (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s43770 · Cited by 245
Mutations in the Desert hedgehog (DHH) Gene in Patients with 46,XY Complete Pure Gonadal Dysgenesis
Canto, P., Söderlund, D., Reyes, E., & Méndez, J. P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0863 · Cited by 243
Hyperthermia using nanoparticles – Promises and pitfalls
Kaur, P., Aliru, M. L., Chadha, A. S., Asea, A., & Krishnan, S. (2016) · International Journal of Hyperthermia · doi:10.3109/02656736.2015.1120889 · Cited by 228
Therapeutic targets of triple‐negative breast cancer: a review
Jamdade, V. S., Sethi, N., Mundhe, N. A., Kumar, P., Lahkar, M., & Sinha, N. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13211 · Cited by 205
Ko, J., Carpenter, E., & Issadore, D. (2016) · The Analyst · doi:10.1039/c5an01610j · Cited by 202
Cannabinoids as therapeutic agents in cancer: current status and future implications
Chakravarti, B., Ravi, J., & Ganju, R. K. (2014) · Oncotarget · doi:10.18632/oncotarget.2233 · Cited by 200
ICAM-1 as a molecular target for triple negative breast cancer
Guo, P., Huang, J., Wang, L., Jia, D., Yang, J., Dillon, D. A., Zurakowski, D., Mao, H., Moses, M. A., & Auguste, D. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408556111 · Cited by 192
CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
Wang, X., Osada, T., Wang, Y., Yu, L., Sakakura, K., Katayama, A., McCarthy, J. B., Brufsky, A., Chivukula, M., Khoury, T., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq343 · Cited by 188
Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition
Miele, L., Espinoza, I., Pochampally, Watabe, & Xing, F. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s36162 · Cited by 183
Imaging of triple-negative breast cancer
Dogan, B. E., & Turnbull, L. W. (2012) · Annals of Oncology · doi:10.1093/annonc/mds191 · Cited by 182
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials
Scheinberg, D. A., Villa, C. H., Escorcia, F. E., & McDevitt, M. R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.38 · Cited by 180
Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer
Cascione, L., Gasparini, P., Lovat, F., Carasi, S., Pulvirenti, A., Ferro, A., Alder, H., He, G., Vecchione, A., Croce, C. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055910 · Cited by 179
Narayan, P., Wahby, S., Gao, J. J., Amiri-Kordestani, L., Ibrahim, A., Bloomquist, E., Tang, S., Xu, Y., Liu, J., Fu, W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3545 · Cited by 178
The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology
Eccles, S. A. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.113396se · Cited by 176
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review)
ZHANG, M. H., Man, H., Zhao, X., DONG, N., & Shi, L. (2013) · Biomedical Reports · doi:10.3892/br.2013.187 · Cited by 175
Cooney, C. A., Jousheghany, F., Yao-Borengasser, A., Phanavanh, B., Gomes, T., Kieber-Emmons, A. M., Siegel, E. R., Suva, L. J., Ferrone, S., Kieber-Emmons, T., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2895 · Cited by 175
Molecular Classification of Triple-Negative Breast Cancer
Ahn, S. G., Kim, S. J., Kim, C., & Jeong, J. (2016) · Journal of Breast Cancer · doi:10.4048/jbc.2016.19.3.223 · Cited by 174
The paradoxical functions of EGFR during breast cancer progression
Ali, R., & Wendt, M. K. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.42 · Cited by 167
Palomero, T., Barnes, K. C., Real, P. J., Glade Bender, J. L., Sulis, M. L., Murty, V. V., Colovai, A. I., Balbin, M., & Ferrando, A. A. (2006) · Leukemia · doi:10.1038/sj.leu.2404258 · Cited by 166
Evidence for the Notch Signaling Pathway on the Role of Estrogen in Angiogenesis
Soares, R. A., Balogh, G., Guo, S., Gärtner, F., Russo, J., & Schmitt, F. C. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0362 · Cited by 165
Targeting EGFR in Triple Negative Breast Cancer
Ueno, N. T., & Zhang, D. (2011) · Journal of Cancer · doi:10.7150/jca.2.324 · Cited by 161
Gerber, B., Loibl, S., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt361 · Cited by 161
He, J., Peng, T., Peng, Y., Ai, L., Deng, Z., Wang, X.-Q., & Tan, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10510 · Cited by 160
Renard, P. L., Jordan, O., Faes, A., Petri‐Fink, A., Hofmann, H., Rüfenacht, D. A., Bosman, F. T., Buchegger, F., & Doelker, É. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.091 · Cited by 158
Jones, L. D., Golan, D., Hanna, S. A., & Ramachandran, M. (2018) · Bone & Joint Research · doi:10.1302/2046-3758.73.bjr-2017-0147.r1 · Cited by 158
Freedman, G. M., Anderson, P. R., Li, T., & Nicolaou, N. (2009) · Cancer · doi:10.1002/cncr.24094 · Cited by 155
Alshaer, W., Hillaireau, H., Vergnaud, J., Mura, S., Deloménie, C., Sauvage, F., Ismail, S. I., & Fattal, E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.022 · Cited by 147
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
Bagnyukova, T., Serebriiskii, I. G., Zhou, Y., Hopper-Borge, E. A., Golemis, E. A., & Astsaturov, I. A. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.9.13738 · Cited by 143
The hedgehog pathway in triple‐negative breast cancer
Habib, J. G., & O’Shaughnessy, J. (2016) · Cancer Medicine · doi:10.1002/cam4.833 · Cited by 140
Dvl2-Dependent Activation of Daam1 and RhoA Regulates Wnt5a-Induced Breast Cancer Cell Migration
Zhu, Y., Tian, Y., Du, J., Hu, Z., Yang, L., Liu, J., & Gu, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037823 · Cited by 131
Singh, R., Swanner, J., Mims, J., Akman, S., Furdui, C., Torti, S., & Carroll, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80349 · Cited by 130
Chen, N., Brachmann, C. B., Liu, X., Pierce, D. W., Dey, J., Kerwin, W. S., Li, Y., Zhou, S. Y., Hou, S., Carleton, M. O., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2833-5 · Cited by 130
Notch2 Signaling Induces Apoptosis and Inhibits Human MDA-MB-231 Xenograft Growth
O’Neill, C. F., Urs, S., Cinelli, C. M., Lincoln, A., Nadeau, R. J., León, R., Toher, J. L., Mouta‐Bellum, C., Friesel, R. E., & Liaw, L. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061029 · Cited by 126
Yang, L. P. H., Cao, Z., Sajja, H. K., Mao, H. Z., Wang, L., Geng, H., Xu, H., Jiang, T., Wood, W. C., Nie, S., et al. (2008) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2008.007 · Cited by 121
Sharma, A., Paranjape, A. N., Rangarajan, A., & Dighe, R. R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0508 · Cited by 121
Self-citationNabholtz, J., Abrial, C., Mouret‐Reynier, M., Dauplat, M.-M., Weber, B. E., Gligorov, J., Forest, A. M., Trédan, O., Vanlemmens, L., Petit, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu183 · Cited by 121
Liao, W., Ho, Y. C., Lin, Y.-W., Raj, E. N., Liu, K., Chen, C., Zhou, X.-Z., Lu, K.-P., & Chao, J. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.025 · Cited by 121
Milane, L. S., Duan, Z., & Amiji, M. M. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.12.009 · Cited by 119
Wang, X., Hu, J., Wang, P., Zhang, S., Liu, Y., Xiong, W., & Liu, Q. (2015) · Theranostics · doi:10.7150/thno.10853 · Cited by 118
Li, K., Lu, L., Xue, C., Liu, J., He, Y., Zhou, J., Xia, Z., Dai, L., Luo, Z. Y., Mao, Y., et al. (2019) · Nanoscale · doi:10.1039/c9nr06505a · Cited by 117
McVeigh, T. P., & Kerin, M. J. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s109847 · Cited by 115
Huang, N., Wang, H., Zhao, J., Lui, H., Korbelik, M., & Zeng, H. (2010) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20968 · Cited by 112
The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy
Hui, M. N., Cazet, A., Nair, R., Watkins, D. N., O'Toole, S. A., & Swarbrick, A. (2013) · Breast Cancer Research · doi:10.1186/bcr3401 · Cited by 112
miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer
Mathe, A., Scott, R. J., & Avery‐Kiejda, K. A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226090 · Cited by 111
Zhang, L., Chuang, L. I. U., Gao, Y., Li, Z., Xing, J., Ren, W., Zhang, L., Li, A., Lu, G., Wu, A., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201801144 · Cited by 110
Ruiz, A., Hernández, Y., Cabal, C., Dalmau, E. G., Veintemillas-Verdaguer, S., Martínez, E., & Morales, M. P. (2013) · Nanoscale · doi:10.1039/c3nr01412f · Cited by 109
Methods for selection of aptamers to protein targets
Kulbachinskiy, A. V. (2007) · Biochemistry (Moscow) · doi:10.1134/s000629790713007x · Cited by 108
Artificial intelligence for breast cancer screening: Opportunity or hype?
Houssami, N., Lee, C. I., Buist, D. S. M., & Tao, D. (2017) · The Breast · doi:10.1016/j.breast.2017.09.003 · Cited by 106
Nanodiamond–Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells
Toh, T. B., Lee, D.-K., Hou, W., Abdullah, L. N., Nguyen, J., Ho, D., & Chow, E. K. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5001108 · Cited by 99
MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis
Lü, L., Mao, X., Shi, P., He, B., Xu, K., Zhang, S., & Wang, J. (2017) · Medicine · doi:10.1097/md.0000000000007085 · Cited by 96
Ahir, M., Bhattacharya, S., Karmakar, S., Mukhopadhyay, A., Mukherjee, S., Ghosh, S., Chattopadhyay, S., Patra, P., & Adhikary, A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.044 · Cited by 93
Signalling Pathways Implicated in Early Mammary Gland Morphogenesis and Breast Cancer
Howard, B. A., & Ashworth, A. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020112 · Cited by 91
Ayala‐Orozco, C., Urban, C., Bishnoi, S. W., Urban, A. S., Charron, H., Mitchell, T., Shea, M. J., Nanda, S., Schiff, R., Halas, N. J., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.038 · Cited by 90
Frasci, G., Comella, P., Rinaldo, M., Iodice, G., Bonito, M. D., D’Aiuto, M., Petrillo, A., Lastoria, S., Siani, C., Comella, G., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn748 · Cited by 90
Elgqvist, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051102 · Cited by 90
Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
Gucalp, A., & Traina, T. A. (2011) · Chemotherapy Research and Practice · doi:10.1155/2011/696208 · Cited by 89
Panoff, J., Hurley, J. E., Takita, C., dos Reis, I. M., Zhao, W. K., Sujoy, V., Gomez, C. R., Jordà, M., Koniaris, L. G., & Wright, J. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1495-1 · Cited by 88
Corda, G., Sala, G., Lattanzio, R., Iezzi, M., Sallese, M., Fragassi, G., Lamolinara, A., Mirza, H., Barcaroli, D., Ermler, S., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4841 · Cited by 88
Role of Notch signaling pathway in pancreatic cancer.
Gao, J., Long, B., & Wang, Z. P. (2017) · Europe PMC (PubMed Central) · Cited by 87
Gold nanorods as new nanochromophores for photothermal therapies
Ratto, F., Matteini, P., Centi, S., Rossi, F., & Pini, R. (2010) · Journal of Biophotonics · doi:10.1002/jbio.201000002 · Cited by 85
Targeting the Hedgehog signaling pathway for cancer therapy
Li, Y., Maitah, M. Y., Ahmad, A., Kong, D., Bao, B., & Sarkar, F. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.617367 · Cited by 81
Nanocomposites: suitable alternatives as antimicrobial agents
Matharu, R. K., Ciric, L., & Edirisinghe, M. J. (2018) · Nanotechnology · doi:10.1088/1361-6528/aabbff · Cited by 79
Dancy, J. G., Wadajkar, A. S., Connolly, N. P., Galisteo, R., Ames, H. M., Peng, S., Tran, N. L., Goloubeva, O. G., Woodworth, G. F., Winkles, J. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax3931 · Cited by 79
Guo, P., You, J., Yang, J., Jia, D., Moses, M. A., & Auguste, D. T. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4004699 · Cited by 78
Blanco, E., Sangai, T., Wu, S., Hsiao, A., Ruiz‐Esparza, G. U., González-Delgado, C. A., Cara, F. E., Granados-Principal, S. M., Evans, K. W., Akçakanat, A., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.27 · Cited by 78
Multiparametric Monitoring of Tumor Response to Chemotherapy by Noninvasive Imaging
Medarova, Z. O., Rashkovetsky, L. G., Pantazopoulos, P., & Moore, A. V. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2001 · Cited by 78
Notch signaling: its roles and therapeutic potential in hematological malignancies
Gu, Y., Masiero, M., & Banham, A. H. (2016) · Oncotarget · doi:10.18632/oncotarget.7772 · Cited by 75
Miller‐Kleinhenz, J. M., Bozeman, E. N., & Yang, L. P. H. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1343 · Cited by 74
Meng, Q., Meng, J., Ran, W., Wang, J., Zhai, Y., Zhang, P., & Li, Y. (2018) · ACS Nano · doi:10.1021/acsnano.7b09210 · Cited by 73
Atkinson, R. L., Yang, W. T., Rosen, D. G., Landis, M. D., Wong, H. H., Lewis, M. T., Creighton, C. J., Sexton, K. R., Hilsenbeck, S. G., Şahin, A. A., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3471 · Cited by 71
Using Gold Nanoparticles To Disrupt the Tumor Microenvironment: An Emerging Therapeutic Strategy
Melamed, J. R., Riley, R., Valcourt, D. M., & Day, E. S. (2016) · ACS Nano · doi:10.1021/acsnano.6b07673 · Cited by 70
Hedgehog signalling in vascular development
Nagase, T., Nagase, M., Machida, M., & Fujita, T. (2008) · Angiogenesis · doi:10.1007/s10456-008-9105-5 · Cited by 69
Wang, L., Peng, C., Chen, C., & Li, Y. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3363-x · Cited by 67
Feng, B., Xu, Z., Zhou, F., Yu, H., Sun, Q., Dangge, W., Tang, Z., Yu, H., Yin, Q., Zhang, Z., et al. (2015) · Nanoscale · doi:10.1039/c5nr03693c · Cited by 66
Bousquet, G., Bouchtaoui, M. E., Tan, S., Lebœuf, C., de BAZELAIRE, C., Ratajczak, P., Giacchetti, S., de Roquancourt, A., Bertheau, P., Verneuil, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16925 · Cited by 66
Ayachi, I. E., Fatima, I., Wend, P., Alva-Ornelas, J. A., Runke, S., Kuenzinger, W. L., Silva, J. D. S., Silva, W., Gray, J. K., Lehr, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1069 · Cited by 65
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
O’Meara, T. A., Safonov, A. M., Casadevall, D., Qing, T., Silber, A. L. M., Killelea, B. K., Hatzis, C., & Pusztai, L. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05156-5 · Cited by 63
Xu, Y., Liu, D., Hu, J., Ding, P., & Chen, M. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118637 · Cited by 63
Shemesh, C. S., Moshkelani, D., & Zhang, H. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1560-7 · Cited by 62
Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies
Aberger, F., Kern, D., Greil, R., & Hartmann, T. N. (2012) · Vitamins and hormones · doi:10.1016/b978-0-12-394622-5.00002-x · Cited by 60
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Ellisen, L. W. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.047 · Cited by 60
Sang, M., Han, L., Luo, R., Qu, W., Zheng, F., Zhang, K., Liu, F., Xue, J., Liu, W., & Feng, F. (2019) · Biomaterials Science · doi:10.1039/c9bm01171d · Cited by 57
The Functional Role of Notch Signaling in Triple-Negative Breast Cancer
Speiser, J. J., Erşahin, Ç. H., & Osipo, C. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00013-7 · Cited by 51
Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast Cancers
Cao, Y. J., Axup, J. Y., Ma, J. S. Y., Wang, R. E., Choi, S., Tardif, V., Lim, R. K. V., Pugh, H. M., Lawson, B. R., Welzel, G., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500799 · Cited by 51
Purification and Magnetic Interrogation of Hybrid Au‐Fe3O4 and FePt‐Fe3O4 Nanoparticles
Beveridge, J. S., Buck, M. R., Bondi, J. F., Misra, R., Schiffer, P., Schaak, R. E., & Williams, M. E. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201104829 · Cited by 49
Lee, E., Choi, A., Jun, Y., Kim, N. H., Yook, J. I., Kim, S. Y., Lee, S., & Kang, S. W. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101391 · Cited by 49
Immunotargeting of Cancer Stem Cells
Köseer, A. S., Gaetano, S. D., Arndt, C., Bachmann, M. P., & Dubrovska, A. (2023) · Cancers · doi:10.3390/cancers15051608 · Cited by 49
Layman, R. M., Ruppert, A. S., Lynn, M., Mrózek, E., Ramaswamy, B., Lustberg, M. B., Wesolowski, R., Ottman, S., Carothers, S., Bingman, A. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2112-2 · Cited by 48
Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system
Zhang, W., Meng, J., Ji, Y., Li, X., Kong, H., Wu, X., & Xu, H. (2011) · Nanoscale · doi:10.1039/c1nr10573f · Cited by 47
Vyas, D., Lopez‐Hisijos, N., Gandhi, S., El‐Dakdouki, M. H., Basson, M. D., Walsh, M. F., Huang, X., Vyas, A. K., & Chaturvedi, L. S. (2015) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2015.10834 · Cited by 45
Ezzat, A. A., Ibrahim, E. M., Ajarim, D. S., Rahal, M. M., Raja, M. A., Tulbah, A. M., Almalik, O., Alshabanah, M., & Sörbris, R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601616 · Cited by 44
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Almansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
Rahim, M. A., Jan, N., Khan, S., Shah, H., Madni, A., Khan, A., Jabar, A., Khan, S., Elhissi, A., Hussain, Z., et al. (2021) · Cancers · doi:10.3390/cancers13040670 · Cited by 323
Biological Function of Long Non-coding RNA (LncRNA) Xist
Wang, W., Min, L., Qiu, X., Wu, X., Liu, C., Ma, J., Zhang, D., & Zhu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645647 · Cited by 248
Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer
Yousafzai, N. A., El Khalki, L., Wang, W., Szpendyk, J., & Sossey-Alaoui, K. (2024) · Cancers · doi:10.3390/cancers16050883 · Cited by 20
Metadata
- Authors
- Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T.
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2020-03-20
- Volume
- 17
- Issue
- 6
- Pages
- 2078
- ISSN
- 1660-4601 (ISSN-L)
- OpenAlex
- W3012440210
- Cited by
- 333
- References
- 217
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.